NCT06370728View on ClinicalTrials.gov

A Drug-Drug Interaction (DDI) Study of Orforglipron With Carbamazepine in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 6, 2024

Primary Completion Date

July 23, 2024

Study Completion Date

July 23, 2024

Conditions
Healthy
Interventions
DRUG

Orforglipron

Administered orally

DRUG

Carbamazepine

Administered orally

Trial Locations (1)

78209

ICON Early Phase Services, San Antonio

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT06370728 - A Drug-Drug Interaction (DDI) Study of Orforglipron With Carbamazepine in Healthy Participants | Biotech Hunter | Biotech Hunter